Choroideremia Treatment Market Outlook:
Choroideremia Treatment Market size was valued at USD 9.79 billion in 2025 and is likely to cross USD 15.65 billion by 2035, expanding at more than 4.8% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of choroideremia treatment is assessed at USD 10.21 billion.
The growth of this market can be ascribed to the increasing prevalence of choroideremia all across the globe. 1 in 50,000 to 100,000 people in the United States has choroideremia according to the Centers for Disease Control and Prevention.
Due to the delay in diagnosis and treatment of patients with choroideremia, COVID-19 is likely to have an important effect on the therapeutic market for choroideremia. Anyhow, the result will be short-term and post-COVID-19 pandemic, the choroideremia treatment market will show a significant surge owing to an increase in treatment adoption.
Key Choroideremia Treatment Market Insights Summary:
Regional Highlights:
- North America is projected to hold the largest revenue share of 35% by 2035, impelled by its status as a hub of healthcare innovation and technology.
- The Asia Pacific market is anticipated to grow significantly by 2035, driven by rising disposable incomes and increasing affordability of costly treatments.
Segment Insights:
- The ophthalmic segment is projected to account for around 40% share by 2035, propelled by the increasing integration of gene therapy in the ophthalmic route of administration.
- The hospital pharmacies segment is anticipated to hold over 40% revenue share by 2035, driven by their role as central distribution points for specialized and high-cost medications.
Key Growth Trends:
- Growing advancement in medical technology
- Favorable government policies
Major Challenges:
- Complex disease pathology
- Side effects and safety issues associated with the treatment
Key Players: A&T Well and Pump, A Plus Well Service Inc., Acona AS, AGR Holdco Ltd., BiSN Oil Tools Ltd., Calfrac Well Services Ltd., Coretrax Ltd., Dan Wood Co., Expro Group Holdings NV, Halliburton Co., Weatherford International, Japan Oil Development Co., Ltd., Japan Petroleum Exploration Co., Ltd., Air Liquide Japan G.K., Inpex Corporation.
Global Choroideremia Treatment Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 9.79 billion
- 2026 Market Size: USD 10.21 billion
- Projected Market Size: USD 15.65 billion by 2035
- Growth Forecasts: 4.8% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (35% Share by 2035)
- Fastest Growing Region: North America
- Dominating Countries: United States, United Kingdom, Germany, Japan, France
- Emerging Countries: USA, Canada, Japan, Germany, UK
Last updated on : 25 February, 2026
Choroideremia Treatment Market - Growth Drivers and Challenges
Growth Drivers
-
Growing advancement in medical technology - One of the main factors propelling the market for choroideremia treatments is advancements in healthcare technologies. Numerous advancements over the past several years have resulted in novel choroideremia therapy options.
These advancements not only expanded the pool of treatments available but also improved accessibility to them. Patients can now better manage their symptoms and improve their quality of life because of the medications' increased efficacy. - Favorable government policies - Globally, governments are becoming more proactive in fostering the development and availability of treatments for rare diseases such as choroideremia. Patients now have more access to medicines and treatments that can help regulate their symptoms as a result of this assistance, which has also stimulated innovation and investment in the field.
Challenges
-
Complex disease pathology - Choroideremia is caused by mutations in the CHM gene that affect the production of a protein essential for the proper function of the retina. The complex interplay between genetics, cellular processes, and visual function makes it challenging to develop effective therapies.
-
Side effects and safety issues associated with the treatment.
- Limited access to specialty is another factor posing limitations on the choroideremia treatment market growth in the near future.
Choroideremia Treatment Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
4.8% |
|
Base Year Market Size (2025) |
USD 9.79 billion |
|
Forecast Year Market Size (2035) |
USD 15.65 billion |
|
Regional Scope |
|
Choroideremia Treatment Market Segmentation:
Route of Administration Segment Analysis
In choroideremia treatment market, ophthalmic segment is likely to account for around 40% share by 2035. The growth of this segment can be attributed on account of increasing integration of gene therapy in ophthalmic route of administration.
Gene therapy is regarded as a promising approach for treating choroideremia and its adoption is anticipated to rise in the upcoming years. This is owing to factors such as enhanced safety and efficacy profiles of gene therapy vectors and increasing clinical trial data supporting its effectiveness. Biogen Inc. initiated a Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia.
Distribution Channel Segment Analysis
In choroideremia treatment market, hospital pharmacies segment is predicted to hold more than 40% revenue share by 2035. Hospital pharmacies often serve as the central distribution point for specialized and high-cost medications such as those targeted for rare diseases like choroideremia.
This efficiency in supply chain management could benefit patients by ensuring timely access to treatment. Furthermore, as new choroideremia treatments especially gene therapy approaches reach the market, innovative reimbursement pathways are being explored. Hospital pharmacies are likely to play a crucial role in navigating these play a key role in navigating these reimbursement complexities and facilitating patient access to treatment.
Our in-depth analysis of the global choroideremia treatment market includes the following segments:
|
Therapy |
|
|
Administration |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Choroideremia Treatment Market - Regional Analysis
North American Market Insights
North America industry is set to hold largest revenue share of 35% by 2035. North America is an epicenter of innovation and technology that has helped the region establish itself as a leader in the healthcare industry.
This is also true for the market for choroideremia treatments in North America, where developments in R&D are propelling the industry to new heights. A number of clinical centres that focus on the diagnosis and treatment of choroideremia could potentially account for the growth. Numerous services are provided by these centres, including genetic testing, rehabilitation for individuals with limited vision, and access to experimental medications like gene therapy.
For occasion, the Choroideremia Inquire about Establishment CRFC is a nongovernmental organization committed to financing and investigating on potential medications and cures for Choroideremia in Canada
APAC Market Insights
The market in the Asia Pacific region is predicted to grow significantly by the end of 2035. The Asia Pacific region is experiencing rapid economic growth leading to escalating disposable incomes in many countries. This makes patients more willing and able to afford costly choroideremia treatments.
Governments in the region are also investing highly in infrastructure, making advanced treatments more accessible to patients. Furthermore, recent advancements in gene therapy and optogenetics hold promise for the development of more effective treatments for choroideremia. Several clinical trials are currently underway in the Asia Pacific region for novel therapies that could boost growth of the choroideremia treatment market in the future.
Choroideremia Treatment Market Players:
- Novartis AG
- Spark Therapeutics
- Bluebird Bio Inc.
- Biogen Inc.
- Copernicus Therapeutics, Inc.
- 4D Molecular Therapeutics
- Wize Pharma Inc.
- Retina Implant AG
- Hoffmann-La Roche Ltd
- Kiora Pharmaceuticals
- Astellas Pharma Inc.
- Pixium Vision
Recent Developments
- Biogen Inc., announced that the final patient has been enrolled in the international Phase 3 STAR clinical trial evaluating timrepigen-emparvovec, an experimental gene therapy for the treatment of choroideremia.
- Astellas Pharma and 4D Molecular Therapeutics, Inc. acquire rights for Astellas to use the R100* intravitreal retinotropic vector invented by 4DMT for gene targets involved in rare monogenic eye diseases Announced license agreement (with option to add up to two additional targets) for an additional option exercise fee, potentially implicating rare monogenic eye diseases. R100 is a vector invented by 4DMT for intravitreally delivery of the adeno-associated virus, AAV. It's capable of breaking into the internal membrane wall and effectively transducing the whole retina, resulting in a strong gene expression for retinal cells. The R100 vector is used, including 4D-150 in wet agerelated macular degeneration and diabetic macular edema, by all the three clinical stage4DMT ophthalmic product candidates.
- Report ID: 5519
- Published Date: Feb 25, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Choroideremia Treatment Market Report Scope
Free Sample includes current and historical market size, growth trends, regional charts & tables, company profiles, segment-wise forecasts, and more.
Connect with our Expert
Copyright @ 2026 Research Nester. All Rights Reserved.
